AzTrials
AzTrials

Renal TransplantNCT06707272

A Study of the Correlation Between Donor UDP-Glc and Transplanted Kidney Function

An observational study of Renal Transplant, run by Qianghua Leng at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Kidney transplantation is the preferred treatment for end-stage renal disease (ESRD), however, organ shortage is the primary bottleneck restricting the progression of organ transplantation.1 Organs from Expanded Criteria Donors (ECD) have the potential to greatly increase the donor organ pool. Read more about this study

Who is it for?
Any age
Conditions the study is for
Renal Transplant
How many people
200 participants
Where
1 siteChina
Study dates
1 Jun 2023to 10 Oct 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: This a single-center observational clinical study included recipients who underwent successful kidney transplantation and had donor urine samples at our center between June 2023 and August 2024.

Who may be able to join

  • donors who met the criteria for kidney donation
  • recipients who met the criteria for kidney transplantation
  • informed consent form signed
  • organs from deceased donors
  • completed the family consent form for human organ donation.

Who cannot join

  • donors without urine samples
  • recipients with multiple organ transplantation
  • participation in other clinical trials
  • recipients died in perioperation period
  • recipients experienced kidney transplant nephrectomy in perioperation period
  • recipients did not have a follow-up visit at our center with 1 month after being first discharged
  • other features considered unsuitable by researchers.

Trial locations and contacts

1 site in 1 country.

China1 site
  • The Third Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, 510000

Other trials in China

About this study

Kidney transplantation is the preferred treatment for end-stage renal disease (ESRD), however, organ shortage is the primary bottleneck restricting the progression of organ transplantation.1 Organs from Expanded Criteria Donors (ECD) have the potential to greatly increase the donor organ pool. However, they also require careful selection and utilization. Deceased kidney donors often had a history of central nervous system fluid regulation disorders and inflammation mediator release, which led to hemodynamic instability, electrolyte and acid-base imbalances, and with a higher risk of primary graft non-function (PNF) or delayed graft function (DGF) post-transplantation.2,3 Searching for appropriate and effective biomarkers to assess renal quality and predict DGF is a hot topic in the field of kidney transplantation.

Uridine diphosphate-glucose (UDP-Glc) is a damage-associated molecular pattern molecule (DAMPs) released by damaged cells.4 UDP-Glc is synthesized in the cytoplasm, then transported into the lumen of the endoplasmic reticulum and Golgi apparatus, where it regulates the synthesis of carbohydrates and acts as a substrate to facilitate glycosylation reactions.5 And UDP-Glc is an endogenous excitant of the G protein-coupled P2Y14 receptor.6 Additionally, the human P2Y14 receptor is expressed at high levels in adipose tissue, stomach, intestines, specific regions of the brain, skeletal muscle, spleen, lungs, and heart.7 UDP-Glc released plays a significant role in extracellular signaling within these tissues.8 Activation of P2Y14 promotes neutrophil infiltration, the recruitment of monocytes and macrophages, and the activation of the immune response, ultimately leading to tissue damage.9 Research has discovered that intercalated cells (ICs) in the collecting duct of the kidney act as sensors for UDP-Glc, and when the P2Y14 receptor on their apical membrane is activated, ICs produce chemotactic cytokines that attract neutrophils to the kidney, causing kidney inflammation and the onset of acute kidney injury (AKI).10,11 Furthermore, studies have shown that the concentration of UDP-Glc in the urine of AKI patients is higher compared to patients without AKI.12 UDP-Glc hydrolyzes slowly in the extracellular environment, which results in UDP-Glc being highly stable and easily detectable.5,13 In conclusion, donor urinary UDP-Glc can be serve as an appropriate and effective biomarkers to assess renal quality and predict DGF.

The study aimed to investigated the correlation between donor urinary UDP-Glc levels and graft function post-transplant in recipients. We hypothesized that the higher the donor urinary UDP-Glc levels, the more severe the kidney damage, resulting in a higher probability of DGF. It will provide transplant surgeons with a novel strategy to predict DGF earlier and more accurately without invasive procedures, while also reducing medical costs.

Keywords
renal transplant, delayed graft function, acute kidney injury
Medical subject headings
Delayed Graft Function, Acute Kidney Injury

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT06707272
Study groupRoleWhat they receive
delayed graft functionDelay graft function (DGF) was defined as the need for dialysis treatment within the first week following transplantation or Scr at post-transplant 1 week (POW1) ≥ 4.52 mg/dL.
Immediate graft functionImmediate graft function (IGF) was defined as Scr at POW1 < 2.50 mg/dL, and slow graft function (SGF) was defined as Scr at POW1 ≥ 2.50 mg/dL.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Post-transplant renal function

    Assessment of patients' renal function recovery by serum creatinine values after renal transplantation

    Measured: Within 7 days of kidney transplantation

Secondary outcomes (1)
  1. Survival time of transplanted kidneys

    Measured: Within 1 year after kidney transplantation

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Nov 2024
  2. Study start1 Jun 2023
  3. Primary completion31 Aug 2024
  4. Study completion10 Oct 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
200 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06707272
Sponsor's protocol ID
II2024-047-02
Status last verified
Nov 2024
First submitted
24 Nov 2024
Last updated
3 Dec 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Raw and post-statistical data

Publications

  • Ma M, Han F, Leng Q, Chen X, Tang Z, Zhang J, Luo Y, Zhang Y, Huang Z, Na N. Preoperative donor urinary UDP-Glc as an independent risk factor for delayed graft function. Front Immunol. 2025 Mar 17;16:1545280. doi: 10.3389/fimmu.2025.1545280. eCollection 2025.

    PubMed 40165952

Questions about this trial

What is this clinical trial studying?

An observational study of Renal Transplant, run by Qianghua Leng at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Post-transplant renal function (time frame: Within 7 days of kidney transplantation). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06707272, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Dec 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in